Opko Health expects to be able to fund its operations into early 2010 after an investment group controlled by the company's chairman and CEO agreed to by $20 million worth of the ophthalmic drug and device shop's stock, according to a US Securities and Exchange Commission filing published this week.

Also in the filing, Opko disclosed its financial results for 2008 and provided an update on a legal dispute in which it has been charged with illegally interfering with the business of a rival.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.